Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management (FLARE)

Novo Nordisk

Status: Invitation-only

Conditions: Chronic Kidney Disease; Atherosclerotic Cardiovascular Disease; Heart Failure

Treatments: Other: No treatment given

Study type: Observational

Funder types: Industry

Identifiers

NCT07160829

DAS-8416

U1111-1315-0755 (Other Identifier)

Details and patient eligibility

About

This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). Study participants will be recruited to complete self-administered online survey. The purpose of this research is to gather real-world evidence related to attitudes around systemic inflammation and specifically the awareness, perception, drivers and barriers, and use of hsCRP in clinical practice to identify systemic inflammation in people with ASCVD+CKD and HF.

Enrollment: 608 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Male or female, age above 18 years at the time of signing informed consent.
• Is a nephrologist or cardiologist. Cardiologists may be a mix of Interventional Cardiology, Heart Failure (HF) Specialist, General Cardiology, Preventative Cardiology, Cardiac Electrophysiology, Cardio-Oncology or Echocardiography (India only).
• Has been in specialty practice greater than or equal to 3 years.
• If cardiologist, sees at least 15 people with Atherosclerotic Cardiovascular Disease (ASCVD) with or without Chronic Kidney Disease (CKD) per month.
• If nephrologist, sees at least 20 people with ASCVD and CKD per month.

Exclusion criteria

• Previous participation in this study. Participation is defined as having given informed consent in this study.
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
• If nephrologist, is only using dialysis to treat people with ASCVD and CKD.
• Does not meet inclusion criteria requirements.

Trial design

608 participants in 2 patient groups

Nephrologist Group

Description:

This group includes nephrologists treating people with ASCVD and CKD.

Treatment:

Other: No treatment given

Cardiologist Group

Description:

This group includes cardiologist treating people with ASCVD and CKD.

Treatment:

Other: No treatment given